8-K: Alnylam's AMVUTTRA Receives FDA Approval for ATTR Cardiomyopathy, Offering New Hope for Patients

Alnylam's AMVUTTRA (vutrisiran) gains FDA approval for treating cardiomyopathy in adults with transthyretin-mediated amyloidosis (ATTR-CM), reducing cardiovascular mortality and hospitalizations.

Summary

• Alnylam Pharmaceuticals announced that the FDA approved AMVUTTRA (vutrisiran) for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.
• The approval is intended to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits.
• AMVUTTRA is now the first and only therapeutic approved by the FDA for both ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
• ATTR-CM affects approximately 150,000 people in the U.S. and over 300,000 people worldwide.
• AMVUTTRA is an RNAi therapeutic administered via subcutaneous injection four times per year.
• The HELIOS-B Phase 3 clinical trial showed a 28% reduction in the risk of all-cause mortality (ACM) and recurrent cardiovascular (CV) events during the double-blind treatment period of up to 36 months.
• Mortality was reduced by 36% through 42 months in a pre-specified secondary endpoint analysis.
• In the monotherapy population, AMVUTTRA reduced the risk of ACM and recurrent CV events by 33% in the double-blind period and reduced the risk of mortality by 35% through 42 months.
• Alnylam expects similar broad insurance coverage and out-of-pocket costs for AMVUTTRA in ATTR-CM as seen in hATTR-PN, where most patients pay $0 out-of-pocket.
• Marketing authorization applications are under review by global health agencies, including the EMA, ANVISA, and PMDA.
• Alnylam plans to proceed with additional global regulatory submissions for vutrisiran in 2025.

Sentiment

Score: 9

Explanation: The document is highly positive due to the FDA approval of AMVUTTRA for ATTR-CM, strong clinical trial results, and anticipated broad patient access. This approval represents a significant advancement in the treatment of a serious disease.

Positives

• FDA approval expands the indication for AMVUTTRA to include ATTR-CM, addressing a significant unmet need.
• Clinical trial results demonstrate a reduction in cardiovascular mortality and hospitalizations.
• AMVUTTRA offers a new mechanism of action for treating ATTR-CM by reducing TTR production.
• The drug is administered only four times per year, improving patient convenience.
• Alnylam has a patient support program (Alnylam Assist) to help patients navigate treatment and access.
• Broad insurance coverage and low out-of-pocket costs are expected, enhancing patient access.

Risks

• Forward-looking statements are subject to risks and uncertainties, including regulatory actions, clinical trial results, and manufacturing delays.
• The company's ability to successfully launch, market, and sell AMVUTTRA globally is subject to various factors.
• Dependence on third parties for development and commercialization of certain products poses a risk.

Future Outlook

Alnylam plans to proceed with additional global regulatory submissions for vutrisiran in 2025 and expects broad insurance coverage and low out-of-pocket costs for AMVUTTRA in ATTR-CM.

Management Comments

• Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam, stated that the FDA approval of AMVUTTRA for ATTR-CM marks a pivotal advancement for patients.
• Ronald Witteles, M.D., HELIOS-B Investigator, noted that the trial enrolled patients who mirror the real-world population and expressed encouragement about vutrisiran's ability to demonstrate meaningful clinical benefits.

Industry Context

This approval positions Alnylam as a leader in RNAi therapeutics for amyloidosis, addressing a significant unmet need in the treatment of ATTR-CM and potentially impacting the standard of care for this disease.

Comparison to Industry Standards

• AMVUTTRA is the first RNAi therapeutic to demonstrate a reduction in cardiovascular death, hospitalizations, and urgent heart failure visits in ATTR-CM patients, setting a new benchmark.
• Existing treatments primarily focus on symptom management, while AMVUTTRA addresses the disease at its source by reducing TTR production.
• Competitors include companies developing TTR stabilizers and other amyloid fibril disruptors, but AMVUTTRA's RNAi mechanism offers a differentiated approach.

Stakeholder Impact

• Patients with ATTR-CM will have a new treatment option that can reduce cardiovascular mortality and hospitalizations.
• Healthcare providers will have a new tool to manage ATTR-CM.
• Alnylam's shareholders may benefit from increased revenue and market share.
• Employees of Alnylam may experience increased job security and opportunities for advancement.

Next Steps

• Alnylam will continue to work with global health agencies to secure marketing authorizations for AMVUTTRA.
• The company will focus on launching and marketing AMVUTTRA to ensure broad patient access.
• Alnylam will continue to innovate for patients with ATTR amyloidosis.

Key Dates

Keywords

AMVUTTRA, vutrisiran, ATTR-CM, hATTR-PN, Alnylam, FDA approval, RNAi therapeutics, Cardiomyopathy, Amyloidosis, Transthyretin